{"id":"brentuximab-vedotin-bv","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Peripheral neuropathy"},{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Thrombocytopenia"},{"rate":"30-40","effect":"Nausea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Fever"},{"rate":"10-20","effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of a chimeric anti-CD30 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent. Upon binding to CD30-expressing cells, the conjugate is internalized and the toxin is released intracellularly, causing mitotic arrest and apoptosis. This targeted delivery mechanism allows concentration of cytotoxic activity in CD30-positive tumor cells while minimizing systemic toxicity.","oneSentence":"Brentuximab vedotin is an antibody-drug conjugate that binds to CD30 on tumor cells and delivers a microtubule-disrupting toxin to induce cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:37.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma (relapsed or refractory)"},{"name":"Systemic anaplastic large cell lymphoma (relapsed or refractory)"},{"name":"Primary cutaneous anaplastic large cell lymphoma"},{"name":"Mycosis fungoides (cutaneous T-cell lymphoma)"}]},"trialDetails":[{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT07467317","phase":"","title":"BV-CHP Real-life and Biological Evidences in Patients With sALCL","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2026-05","conditions":"Anaplastic Large Cell Lymphoma","enrollment":100},{"nctId":"NCT03652441","phase":"PHASE2","title":"Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2019-11-13","conditions":"Classical Hodgkin Lymphoma","enrollment":14},{"nctId":"NCT02684292","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-23","conditions":"Hodgkin Lymphoma","enrollment":304},{"nctId":"NCT07275216","phase":"PHASE2","title":"Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-01","conditions":"Classic Hodgkin Lymphoma","enrollment":23},{"nctId":"NCT07258680","phase":"PHASE3","title":"BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas","status":"ENROLLING_BY_INVITATION","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2013-10","conditions":"Peripheral T-cell Lymphoma","enrollment":114},{"nctId":"NCT02227199","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Washington","startDate":"2014-10-10","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":45},{"nctId":"NCT03113500","phase":"PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-05-25","conditions":"Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":48},{"nctId":"NCT07013565","phase":"PHASE2","title":"Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2025-08-07","conditions":"Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":20},{"nctId":"NCT03233347","phase":"PHASE2","title":"Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2017-10-13","conditions":"Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma","enrollment":82},{"nctId":"NCT06925555","phase":"PHASE2","title":"Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09","conditions":"EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin","enrollment":25},{"nctId":"NCT07178457","phase":"PHASE3","title":"Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-11-01","conditions":"Cutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin","enrollment":84},{"nctId":"NCT07171827","phase":"NA","title":"Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Helwan University","startDate":"2023-03-01","conditions":"Anti-CD30, Brentuximab, Doxorubicin","enrollment":60},{"nctId":"NCT05100056","phase":"","title":"A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Takeda","startDate":"2022-03-08","conditions":"Hodgkin Lymphoma","enrollment":70},{"nctId":"NCT02734771","phase":"PHASE2","title":"A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick Reagan","startDate":"2016-06","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT05414500","phase":"PHASE1","title":"Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-05-01","conditions":"Cutaneous T Cell Lymphoma, Mycosis Fungoides","enrollment":10},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT06377566","phase":"PHASE2","title":"A Study of BV-AVD in People With Bulky Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-04-17","conditions":"Hodgkin Lymphoma","enrollment":71},{"nctId":"NCT02744612","phase":"PHASE2","title":"Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2016-06-20","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":39},{"nctId":"NCT03264131","phase":"PHASE2","title":"BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-10-11","conditions":"Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases","enrollment":16},{"nctId":"NCT02927769","phase":"PHASE2","title":"A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-28","conditions":"Hodgkin Disease","enrollment":72},{"nctId":"NCT06761911","phase":"PHASE4","title":"BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Xiuhua Sun","startDate":"2024-12-31","conditions":"Hodgkin Lymphoma (Category)","enrollment":100},{"nctId":"NCT05886478","phase":"","title":"A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-02-08","conditions":"T-Cell Lymphoma","enrollment":26},{"nctId":"NCT04998331","phase":"","title":"A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-10-29","conditions":"Hodgkin Disease, Lymphoma, T-Cell, Cutaneous","enrollment":51},{"nctId":"NCT05404945","phase":"PHASE2","title":"Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2022-07-26","conditions":"Classical Hodgkin Lymphoma","enrollment":44},{"nctId":"NCT03217643","phase":"PHASE2","title":"CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.","status":"COMPLETED","sponsor":"Imagine Institute","startDate":"2018-02-07","conditions":"Enteropathy Associated T-cell Lymphoma","enrollment":14},{"nctId":"NCT01979536","phase":"PHASE2","title":"Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-11-13","conditions":"Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma","enrollment":137},{"nctId":"NCT03576378","phase":"PHASE1, PHASE2","title":"BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)","status":"UNKNOWN","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2018-08-08","conditions":"Hodgkin Lymphoma","enrollment":41},{"nctId":"NCT04378647","phase":"PHASE2","title":"BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant","status":"RECRUITING","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2020-06-01","conditions":"Hodgkin Lymphoma, Adult","enrollment":150},{"nctId":"NCT06201507","phase":"PHASE2","title":"BV-AVD-R Treatment Children Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","startDate":"2022-10-01","conditions":"Hodgkin Lymphoma","enrollment":44},{"nctId":"NCT05444712","phase":"NA","title":"Transplantation After Complete Response In Patients With T-cell Lymphoma","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-08-01","conditions":"Peripheral T Cell Lymphoma","enrollment":204},{"nctId":"NCT02467946","phase":"PHASE1, PHASE2","title":"Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2016-01-14","conditions":"Clinical Efficacy, Safety","enrollment":60},{"nctId":"NCT02292979","phase":"PHASE2","title":"Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2015-03","conditions":"Hodgkin Lymphoma","enrollment":170},{"nctId":"NCT05316246","phase":"PHASE2","title":"Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-06-01","conditions":"NK/T Cell Lymphoma Nos","enrollment":40},{"nctId":"NCT02686346","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-03","conditions":"Hodgkin Disease","enrollment":53},{"nctId":"NCT02227433","phase":"PHASE2","title":"Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2013-02-04","conditions":"Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03440788","phase":"","title":"Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin","status":"UNKNOWN","sponsor":"Multinational Center for Quality of Life Research, Russia","startDate":"2018-04-02","conditions":"Relapsed or Refractory Hodgkin's Lymphoma","enrollment":70},{"nctId":"NCT02243436","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2014-11-11","conditions":"CLASSICAL HODGKIN LYMPHOMA","enrollment":67},{"nctId":"NCT01925612","phase":"PHASE2","title":"Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)","status":"TERMINATED","sponsor":"Seagen Inc.","startDate":"2013-08","conditions":"Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse","enrollment":87},{"nctId":"NCT03540849","phase":"PHASE2","title":"BV After Allogeneic Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2018-03-07","conditions":"Hodgkin Lymphoma","enrollment":58},{"nctId":"NCT02280993","phase":"PHASE1","title":"Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients","status":"UNKNOWN","sponsor":"Marjolein Spiering","startDate":"2014-05","conditions":"Hodgkin Lymphoma, Refractory, Relapse","enrollment":72},{"nctId":"NCT00947856","phase":"PHASE2","title":"A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2009-07","conditions":"Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin","enrollment":110},{"nctId":"NCT02275598","phase":"PHASE2","title":"Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"University of Modena and Reggio Emilia","startDate":"2013-04","conditions":"Hodgkin Lymphoma","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BV","Adcetris"],"phase":"marketed","status":"active","brandName":"Brentuximab Vedotin (Bv)","genericName":"Brentuximab Vedotin (Bv)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brentuximab vedotin is an antibody-drug conjugate that binds to CD30 on tumor cells and delivers a microtubule-disrupting toxin to induce cell death. Used for Hodgkin lymphoma (relapsed or refractory), Systemic anaplastic large cell lymphoma (relapsed or refractory), Primary cutaneous anaplastic large cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}